Skip to Main Content

Paper Details

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Diabetes Obes Metab
13
2022
Dallas steatosis, Empagliflozin, cardiovascular disease, empagliflozin, fibrosis, hepatic steatosis, liver steatosis, non-alcoholic fatty liver disease, participants, people, steatosis, type 2 diabetes
Author NameAffiliation
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, BHF Glasgow Cardiovascular Research Centre (GCRC)
Michael RodenInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University
Michael RodenMedical Faculty and University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf
Michael RodenGerman Center for Diabetes Research
  • 1 - 5

Datasets

Release 1.2